Biodexa Pharmaceuticals plc Stock Price, News & Analysis

Biodexa Pharmaceuticals (NASDAQ: BDRX) has implemented its previously announced American Depositary Receipts (ADR) ratio change effective July 31, 2025. The new ratio changes from 1 ADR representing 10,000 ordinary shares to 1 ADR representing 100,000 ordinary shares.

The ratio change functions similarly to a 1-for-10 reverse ADR split, with the exchange occurring automatically through depositary bank JPMorgan Chase Bank. Following the change, the company has 619,523 ADRs outstanding, while the total number of issued ordinary shares remains unchanged at 61,952,308,922.

Biodexa Pharmaceuticals (NASDAQ:BDRX) is advancing its Phase 3 program for eRapa, an oral tablet formulation of rapamycin, to treat Familial Adenomatous Polyposis (FAP). The company has achieved significant regulatory milestones, including FDA Fast Track status and Orphan Drug designation in both US and Europe.

eRapa demonstrated impressive Phase 2 results with an 89% non-progression rate and 29% median reduction in polyp burden at 12 months. The company has initiated its 'Serenta' trial (NCT06950385) in the US and filed a Clinical Trial Application in Europe, targeting a $7 billion addressable market.

With 30 clinical sites identified across the US and Europe, secured funding including a $20 million grant, and potential first-mover advantage, Biodexa is positioned ahead of competitors Recursion Pharmaceuticals (RXRX) and Tempest Therapeutics (TPST) in the race to develop the first approved therapeutic option for FAP.

Biodexa Pharmaceuticals (NASDAQ: BDRX) has announced a significant change in its American Depositary Receipts (ADR) ratio. The company will modify its ADR ratio from 1:10,000 (1 ADR representing 10,000 ordinary shares) to 1:100,000 (1 ADR representing 100,000 ordinary shares), effective July 31, 2025.

ADR holders will be required to exchange their existing ADRs at a ratio of 10:1, with JP Morgan Chase Bank managing the exchange process. This change will effectively function as a 1-for-10 reverse ADR split, though the company's ordinary shares will remain unaffected. The primary goal is to achieve compliance with Nasdaq's minimum bid price requirement of $1.00 per share.

Biodexa Pharmaceuticals (NASDAQ:BDRX) has filed a Clinical Trial Application (CTA) with the European Medicines Agency for its Phase 3 Serenta trial investigating eRapa in Familial Adenomatous Polyposis (FAP). The trial will initially cover clinical sites in Denmark, Germany, Netherlands, and Spain, with Italy to be added later.

The company has achieved several milestones for its eRapa program, including FDA Fast Track Designation, European Orphan Drug designation, and initiation of its first US clinical site. The program is supported by a $20 million grant from CPRIT. The Serenta trial (NCT06950385) is designed as a randomized, double-blind, placebo-controlled Phase 3 study, with European sites expected to begin enrollment in Q4 2025.

Biodexa Pharmaceuticals (NASDAQ: BDRX), a clinical stage biopharmaceutical company, announced that all resolutions proposed at its Annual General Meeting held on June 26, 2025, were successfully passed by shareholders. The company, which focuses on developing innovative treatments for diseases with unmet medical needs, has made the full text of the passed resolutions available on its corporate website under the investor relations section.

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced the activation of its first clinical study site for the Phase 3 Serenta trial, evaluating eRapa in patients with familial adenomatous polyposis (FAP). The trial (NCT06950385) is designed as a randomized, double-blind, placebo-controlled study and is now actively enrolling participants.

The program has received significant support, including $20 million in grant funding from CPRIT, Fast Track Designation, and a positive Type C Meeting. The company has also launched a dedicated website for patient information at serentatrial.com.

Biodexa Pharmaceuticals (NASDAQ: BDRX) has announced 'Serenta' as the brand name for its upcoming Phase 3 clinical study focusing on familial adenomatous polyposis (FAP). The company has launched a dedicated website, www.serentatrial.com, to provide resources and information for patients, caregivers, and healthcare professionals. The website includes details about the study's objectives, FAP background information, and will feature program updates. The study will evaluate eRapa as a treatment for FAP. Chief Medical Officer Gary Shangold emphasized the company's commitment to providing accessible information and engaging with the FAP community throughout the study's progression.

Biodexa Pharmaceuticals (NASDAQ:BDRX) has enrolled its first patient in a Phase 2a trial for Tolimidone, a potential treatment for type 1 diabetes. Originally discovered by Pfizer for gastric ulcers, Tolimidone is being repurposed as it activates the Lyn kinase enzyme, which could help the body produce insulin. The Phase 2a dose confirmation study, conducted with the University of Alberta, will measure C-peptide and HbA1c levels across 12 patients in three dose groups over three months. Preclinical studies at the University of Alberta showed promising results, including beta cell proliferation in human cadaver samples. The global type 1 diabetes treatment market, currently valued at $16.97 billion, is projected to reach $26.22 billion by 2032, growing at a 6.9% CAGR.

Biodexa Pharmaceuticals (NASDAQ: BDRX) held a General Meeting on June 11, 2025, where shareholders approved all four proposed resolutions. Two key outcomes were achieved: First, resolutions 1 and 4 will reduce the nominal (par) value per ordinary share, though the total number of outstanding shares remains unchanged. Second, resolutions 2 and 3 grant the Directors authority to allot ordinary shares on a non-pre-emptive basis, giving them more flexibility in share issuance. The full text of the resolutions is available on the company's website under corporate governance.